GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Quality Rank

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Quality Rank


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Tianjin Pharmaceutical Da Ren Tang Group Quality Rank Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.